Regulus Therapeutics (NASDAQ:RGLS) just reported results for the first quarter of 2024.
- Regulus Therapeutics reported earnings per share of -29 cents. This was below the analyst estimate for EPS of -21 cents.
- The company did not report any revenue for the quarter.